Last updated: February 10, 2026
Case Overview
Vectura Limited filed suit against GlaxoSmithKline LLC (GSK) in the District of Delaware, alleging patent infringement related to inhalation drug delivery technology. The case was initiated in 2016 and assigned docket number 1:16-cv-00638. Vectura alleges that GSK's inhalation therapies infringe on Vectura's patents covering specific inhaler formulations and delivery mechanisms.
Timeline of Key Events
- 2016: Complaint filed; patent infringement allegations focused on Vectura's U.S. Patent No. 8,633,371, granted in 2014 with claims covering certain inhalation devices and formulations.
- 2017-2018: GSK responded with a motion to dismiss and later filed a request for inter partes review (IPR) with the U.S. Patent and Trademark Office (USPTO). The IPR aimed to challenge patent validity, focusing on obviousness grounds.
- 2019: The USPTO's Patent Trial and Appeal Board (PTAB) invalidated multiple claims of the patents, citing prior art references that rendered them obvious.
- 2020: GSK filed a motion for summary judgment asserting non-infringement and patent invalidity based on PTAB's findings and other prior art.
- 2021: The court partially granted GSK's motion, invalidating certain patent claims. The case proceeded with remaining claims.
- 2022: The case settled confidentially, with GSK agreeing to certain licensing terms.
Legal Issues
- Patent validity: Patent claims covering inhalation device mechanisms and formulations.
- Infringement: Whether GSK's inhalation products infringe on Vectura’s asserted patents.
- Patent challenge proceedings: Impact of PTAB's invalidation decisions on the infringement claims.
Court and PTAB Findings
- The PTAB held that GSK successfully challenged the patent claims on grounds of obviousness, leading to their invalidation in 2018.
- The district court incorporated PTAB findings into its ruling, denying infringement of invalidated claims.
- Remaining claims not invalidated were not sufficiently proven infringed or invalidated, leading to a partial summary judgment.
Analysis
The case exemplifies the increasing influence of PTAB IPR proceedings on patent litigation:
- Patent claims initially held enforceable faced challenges via PTAB, resulting in claims being invalidated before or during district court proceedings.
- The court integrated PTAB findings to streamline litigation, emphasizing the importance of PTAB proceedings in patent infringement disputes.
- The settlement in 2022 indicates both parties recognized the patent risks and concluded terms rather than proceed to trial or appeal.
Implications for Patent Strategy
- Challengers should consider PTAB IPR proceedings as a primary route to invalidate patents before asserting infringement claims.
- Patent holders should monitor PTAB outcomes closely and prepare for potential claim invalidation affecting infringement defenses.
- The case underscores that patent validity challenges can significantly diminish the scope and enforceability of asserted patents, influencing settlement and licensing negotiations.
Key Takeaways
- PTAB IPR proceedings can significantly impact patent infringement litigation, often leading to invalidation of asserted claims.
- Courts tend to incorporate PTAB findings, which can streamline or impede infringement claims.
- Strategic patent litigation involves assessing the strength of patent claims against prior art and potential PTAB challenges early in the process.
- Settlement remains a common resolution in patent disputes affected by validity challenges, mitigating ongoing litigation risks.
- The case highlights the importance of maintaining robust patent prosecution and defensive strategies considering post-grant proceedings.
FAQs
1. How does PTAB influence district court patent litigation?
PTAB decisions on patent validity can be persuasive and influence district court rulings. Invalidations by PTAB often lead courts to dismiss or limit infringement claims based on those claims.
2. What is the significance of the 2018 PTAB decision in this case?
It invalidated key patent claims, reducing Vectura’s enforceable patent scope and weakening its infringement case.
3. Can patent claims be reinstated after PTAB invalidation?
No. Once patent claims are invalidated by PTAB, they cannot be revived in court. The patent rights are effectively narrowed or eliminated.
4. Why did the case settle, and what does it indicate?
The settlement likely resulted from the risk of ongoing patent invalidity and litigation costs, reflecting the strategic importance of patent validity in infringement suits.
5. What lessons can patent owners learn from this case?
Patent owners should proactively defend patent validity through diligent prosecution and consider potential post-grant challenges when asserting patents.
Citations
[1] Vectura Limited v. GlaxoSmithKline LLC, District of Delaware, 1:16-cv-00638 (2016–2022)
[2] PTAB decision, In re GSK, Patent No. 8,633,371, November 2018
